BioCryst Pharmaceuticals NASDAQ: BCRX expects revenue to land at the upper end of its $625 million to $645 million guidance range this year, CEO Charlie Gayer said at a Jefferies conference, while outlining plans to expand its hereditary angioedema portfolio and add rare-disease assets.
Gayer said the company expects continued growth for ORLADEYO, its oral treatment for preventing hereditary angioedema (HAE) attacks, although he anticipates growth will eventually plateau as additional competitors enter the market. BioCryst also expects pivotal data next year for navenibart, an investigational injectable treatment for HAE.
ORLADEYO Faces Competition
Gayer said more than 1,600 U.S. patients are taking ORLADEYO, which has been on the market since late 2020, and that more than 1,500 U.S. clinicians have prescribed it this year. The company has been adding more than 60 prescribers per quarter, he said.
Addressing the prospect of competition from another oral prophylactic treatment, deucrictibant, Gayer argued that patients who remain on ORLADEYO experience strong effectiveness. In the APeX-2 study, just over half of patients who started on the 150-milligram dose remained on treatment for two years, and those patients had a 91% reduction in attacks, he said.
In real-world use, about 60% of patients remain on treatment at 12 months, with insufficient effectiveness the leading reason for discontinuation, Gayer said. Among patients with type 1 or type 2 HAE taking ORLADEYO who reported on the preceding six months, 44% reported no attacks and about 70% reported two or fewer, he said.
Gayer said BioCryst’s annual market research suggests patients doing well on ORLADEYO will remain on it despite new alternatives. He estimated the drug’s current share at 22% to 23% across all treated HAE patients, rather than only those receiving preventive therapy, and said BioCryst expects that share to grow into the mid-20% range before leveling off.
Pediatric Launch and Navenibart
BioCryst recently launched ORLADEYO pellets for children ages 2 to 11 and has also received approval for a 150-milligram pellet formulation for patients ages 12 and older, Gayer said. Early pediatric uptake has exceeded the company’s expectations, he added.
Of the children starting the pellets, roughly one-third have switched from another preventive treatment, one-third previously received only acute treatment, and one-third are new to HAE therapy, Gayer said. The company has identified about 500 pediatric patients in claims data, though it estimates the population could be closer to 1,200 based on adult epidemiology.
For navenibart, BioCryst expects pivotal data in the third quarter of next year covering both 12-month and six-month results. Gayer said phase 2 data showed attack reductions of more than 90% versus baseline with durable responses at both three- and six-month dosing intervals.
Gayer said the company sees patients already taking injectable preventive therapies as navenibart’s largest potential market. He also said patients who do not do well on ORLADEYO could potentially switch to navenibart. BioCryst expects to use its existing 40-person sales force for a future launch, without increasing commercial costs as the HAE portfolio grows.
Costs and Pipeline Plans
BioCryst’s operating expense guidance stands at $415 million to $425 million for the year, and Gayer said expenses are expected to fall further in 2027 as the effect of closing discovery facilities is fully realized. The company ended the third quarter with $376 million in cash, he said.
Gayer also expects an update in the coming weeks on BioCryst’s investigational treatment for Netherton syndrome, a rare skin condition. The company plans to report results from up to 12 patients and assess the findings to determine whether to pursue a pivotal study or explore additional doses.
As profitability and cash grow, BioCryst is looking to bring in additional clinical-stage rare-disease assets, Gayer said. Its scientific advisory board is working with the business development team weekly, he said, as the company seeks to build a more balanced pipeline.
About BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals is a biotechnology company that discovers, develops and commercializes medicines for rare diseases. Founded in 1986, the company is headquartered in Durham, North Carolina, and focuses on small-molecule treatments. Its principal product is ORLADEYO (berotralstat), an oral medicine for preventing attacks of hereditary angioedema, a rare condition that causes episodes of swelling. BioCryst also develops medicines for rare diseases, including candidates targeting hereditary angioedema and complement-mediated disorders.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.